MindWalk (HYFT) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MindWalk (HYFT) has outperformed NeOnc Technologies (NTHI) over the past year, losing 23.5% versus a loss of 79.1%. NeOnc Technologies is the larger company by market cap ($80.1 million vs $70.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYFT | NTHI |
|---|---|---|
| Share price | $1.49 | $2.78 |
| Market cap | $70.14M | $80.09M |
| 1-day change | +4.10% | +9.86% |
| YTD return | -21.43% | -69.41% |
| 1-year return | -23.53% | -79.07% |
| 5-year return | -78.27% | — |
| EPS (TTM) | $-0.26 | $-2.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.99 | $12.09 |
| 52-week low | $0.99 | $2.50 |
| Distance from 52-week high | -50.21% | -77.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +190.86% | +511.42% |
| Average volume | 229.74K | 195.17K |
| Shares outstanding | 47.11M | 28.81M |
| Employees | 74 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HYFT has outperformed NTHI by 55.5 percentage points over the past year.
About MindWalk
HYFT stock →MindWalk Holdings Corp. operates as a bio-native AI company.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
HYFT vs NTHI FAQ
Which is bigger, MindWalk or NeOnc Technologies?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $80.09M compared with $70.14M for MindWalk (HYFT).
Which stock has performed better over the past year, HYFT or NTHI?
HYFT returned -23.53% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are MindWalk and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.